Recent Progress in Heart Failure Care
Heart failure (HF) has seen substantial evolution over the past year, marked notably by the joint statement from the Heart Failure Society of America (HFSA) and the American Society for Preventive Cardiology (ASPC). This pivotal statement emphasizes a shift towards preventive care in HF management, advocating for early risk identification and comprehensive cardiovascular care.
The US Food and Drug Administration (FDA) has played a crucial role in enhancing heart failure treatment options through approvals of innovative pharmacotherapeutics. In 2025, the FDA approved bumetanide nasal spray and finerenone, contributing significantly to improving the efficacy and accessibility of HF care.
Key FDA Approvals of 2025
FDA Updates Mavacamten Label in Obstructive Hypertrophic Cardiomyopathy
On April 17, 2025, the FDA updated the prescribing information for mavacamten aimed at adults with New York Heart Association (NYHA) Class II-III obstructive hypertrophic cardiomyopathy (oHCM). Notably, echo monitoring requirements have been reduced, facilitating monitoring frequency from every 12 weeks to every 6 months for qualified patients. This change expands eligibility by removing certain contraindications, thereby enhancing patient access for those requiring this treatment.
FDA Approves Finerenone for Heart Failure with Ejection Fraction of 40% or More
On July 14, 2025, finerenone received FDA approval for reducing cardiovascular risks in adults with heart failure and mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF). This decision stemmed from the FINEARTS-HF trial, demonstrating a 16% reduction in adverse cardiovascular outcomes compared to placebo, emphasizing the potential of finerenone in clinical practice.
FDA Approves Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy
The FDA granted approval for aficamten on December 19, 2025, aiming to alleviate symptoms associated with oHCM, based on the phase 3 SEQUOIA-HCM trial findings that indicated significant improvement in functional capacity versus placebo.
FDA Approves Bumetanide Nasal Spray for Edema with Congestive Heart Failure
On September 15, 2025, bumetanide nasal spray was approved for treating edema associated with congestive heart failure, demonstrating equivalent efficacy to oral formulations while providing a more convenient delivery method. This innovation is anticipated to enhance patient adherence and management of symptoms, marking a significant step forward in HF management.
Shifting to Prevention: New Guidelines and Trials
HFSA and ASPC Call for Prevention in Heart Failure
On August 13, 2025, the HFSA and ASPC advocated for prioritizing prevention and risk identification in HF care. Their guidelines highlight lifestyle modifications, such as better sleep hygiene, regular physical activity, and effective management of cardiovascular risk factors like hypertension and diabetes, as crucial for long-term heart health. They delineate prevention into four major pillars: early risk identification, holistic care, validated therapies, and systemic reform across healthcare practices.
Finerenone Limits Outpatient Oral Diuretic Intensification in Heart Failure
A secondary analysis of the FINEARTS-HF trial affirmed finerenone’s effectiveness in curtailing the need for outpatient oral diuretic intensification, underscoring its role in mitigating worsening heart failure, a critical aspect for managing chronic HF.
Innovative Research Results
DAPA-EAT: Dapagliflozin’s Efficacy in Reducing Epicardial Adipose Tissue
Presenting at the American Heart Association’s Scientific Sessions, the DAPA-EAT trial demonstrated dapagliflozin’s efficacy in reducing epicardial adipose tissue in asymptomatic HF patients, a potential marker for cardiovascular disease. Although echocardiographic results showed no significant changes, dapagliflozin’s ability to improve myocardial structure may have broader implications for HF management.
SURPASS-CVOT: Tirzepatide’s Cardiovascular Benefits
The SURPASS-CVOT clinical trial highlighted tirzepatide as non-inferior to dulaglutide concerning cardiovascular protective effects in patients with type 2 diabetes. Although the study design constraints noted some limitations, the findings support ongoing discussions regarding optimal diabetes management protocols in the context of heart function.
This ongoing evolution in heart failure treatment is significant as HF remains a major public health concern, impacting millions worldwide. With the focus shifting to preventive care and innovative therapies, the medical community is better positioned to address this critical health issue.
